BCMA CAR-NK (Shenzhen Pregene Biopharma) vs Zevorcabtagene autoleucel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

BCMA CAR-NK (Shenzhen Pregene Biopharma)

Developed by Shenzhen Pregene Biopharma Co., Ltd.

Phase 1/2 in Multiple Myelomaallogeneic CAR-NK cell therapy
Weak signal

NCT05652530 · Phase 1 · status unknown

This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 19 participants, and it measured only safety. Results have not been posted yet.

No aligned efficacy figure on record for this race.

Zevorcabtagene autoleucel

Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners

Phase 1/2 in Multiple Myelomacell therapy (autologous BCMA-targeted CAR-T)
Weak signal

NCT03975907 · Phase 1/2 · status unknown

This study enrolled every patient into a single treatment group, with no comparison arm and no blinding, so there is no control group to judge the response rate against. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The registered phase 1 primary endpoint of this study is dose-limiting toxicity; the response rates shown are the phase 2 portion's primary endpoint (overall response rate).

Reported efficacy

Phase 1, Safety and tolerability: dose limiting toxicity (28days post administration of CAR-T-cells); Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate (3 months post administration of CAR-T-cells): LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). (met)

Result source: NCT03975907

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBCMA CAR-NK (Shenzhen Pregene Biopharma)Zevorcabtagene autoleucel
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
Zevorcabtagene autoleucel
—Not reported

OS, median

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
Zevorcabtagene autoleucel
—Not reported

ORR

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
Zevorcabtagene autoleucel
—Not reported

VGPR or better

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
Zevorcabtagene autoleucel
—Not reported

MRD negativity

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
Zevorcabtagene autoleucel
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BCMA CAR-NK (Shenzhen Pregene Biopharma): no structured comparison results are available for Multiple Myeloma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Zevorcabtagene autoleucel
LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). NCT03975907 · Phase 1/2 · design grade: weak · publication or press release
LUMMICAR STUDY 2 (NCT03915184): objective response rate 100% in evaluable relapsed/refractory multiple myeloma patients. NCT03915184 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Shenzhen Pregene Biopharma)'s landscape · Zevorcabtagene autoleucel's landscape